Seoul National University Bundang Hospital (SNUBH)
Medulloblastoma treatment cost in the Republic of Korea typically includes essential diagnostics like a consultation with an oncologist, which ranges from $28 to $100. Primary surgical interventions such as a craniotomy often run $16,500 to $38,000. Total expenses depend on the tumor stage, required radiotherapy cycles, and clinic tier. Patients often find 30% to 50% savings compared to the United States. Top treatment centers are located in Seoul.
Typical Medulloblastoma Treatment Costs in Republic of Korea
Bookimed Expert Insight: Pediatric and adult patients requiring complex brain tumor removal should prioritize JCI-accredited centers like Severance Hospital or SNUH. These facilities utilize AI and digital imaging to enhance surgical safety. For multidisciplinary care, Asan Medical Center is Korea's largest provider, performing over 65,000 operations annually. Expert neurosurgeons like Do Hyun Nam at Samsung Medical Center specialize in endoscopic techniques, offering minimally invasive options for tumor resection.
| Republic of Korea | Turkey | Austria | |
| Craniotomy | from $16,500 | from $5,650 | from $20,000 |
| Stereotaxic radiosurgery | - | from $4,500 | from $17,000 |
| Radiation therapy for colorectal cancer | - | from $7,000 | from $12,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Medulloblastoma treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Medulloblastoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Medulloblastoma treatment journey.
Dr. Do Hyun Nam is a top neurosurgeon in South Korea, specializing in brain tumor removal and endoscopic surgeries at Samsung Medical Center.
Dr. Kim Jin is a colorectal surgeon at Korea University Anam Hospital in Seoul. He is the Vice President of the Korean Association of Robotic Surgeons. Dr. Kim represents South Korea on the board of the Asia Pacific Endo-Lap Surgery Group. He performs surgical demonstrations for medical faculties in Hong Kong and Singapore.
South Korea offers high-tier medulloblastoma treatment through JCI-accredited centers and specialized pediatric neuro-oncology teams. Patients access advanced technologies like stereotaxic radiosurgery and endoscopic brain tumor removal. These facilities provide coordinated oncology and radiation services with significant savings compared to US healthcare costs.
Bookimed Expert Insight: Data shows a clear trend where Korea's largest centers, like Seoul National University Hospital, serve over 10,000 patients daily. This massive volume allows surgeons to see rare medulloblastoma subtypes more frequently than typical Western regional hospitals. Choosing these high-volume state facilities often provides access to the country's most established oncology protocols.
Patient Consensus: Families emphasize the value of fast access to specialized teams that bundle surgery, chemotherapy, and radiation. They note that having all specialists in one system makes managing complex pediatric recovery much easier.
Top South Korean hospitals for medulloblastoma include Seoul National University Hospital, Asan Medical Center, and Severance Hospital. These JCI-accredited facilities use multidisciplinary teams and advanced neurosurgery. Centers like SNUH reported the highest statistics for cancer treatment in the country. Treatment protocols combine surgical resection, radiation, and chemotherapy.
Bookimed Expert Insight: Quality signals for medulloblastoma are found in hospital volume and digital integration. Seoul National University Bundang Hospital uses the unique BESTcare digital system. This infrastructure coordinates care across oncology and neurosurgery departments more efficiently. Such integration is vital for the rapid decision-making required in pediatric brain tumor cases.
Patient Consensus: Families note that successful treatment depends on a unified pediatric neuro-oncology team. Patients emphasize choosing centers that manage surgery, pathology, and radiation in one location.
Medulloblastoma treatment in South Korea follows a multimodal approach starting with surgical resection to remove the tumor. Highly specialized centers utilize craniotomy, followed by targeted chemotherapy and stereotactic radiosurgery. JCI-accredited facilities in Seoul integrate advanced diagnostic tools like CT and long-term MRI follow-up to ensure precision.
Bookimed Expert Insight: South Korea leading centers like Seoul National University Hospital operate as digital hospitals with systems like BESTcare. This digitalization allows for seamless coordination between neurosurgeons and oncologists. Specialized pediatric experts like Dr. Do Hyun Nam focus on endoscopic techniques to reduce recovery times. These institutions manage over 1,000,000 patients yearly, ensuring high surgical volume and clinical expertise.
Patient Consensus: Patients note that treatment is a sequential journey typically moving from operation to radiation and chemotherapy. It is important to plan early for physical and speech therapy to address balance or swallowing issues after surgery.
The overall 5-year survival rate for medulloblastoma exceeds 80% with comprehensive treatment. Outcomes depend primarily on molecular subtype and tumor spread. Standard-risk patients often achieve survival rates between 80% and 90%. High-risk or metastatic cases typically see a 60% survival rate.
Bookimed Expert Insight: South Korea offers a high density of JCI-accredited facilities, like Severance Hospital and Korea University Anam Hospital. Seoul National University Hospital reports some of the highest cancer treatment statistics nationally. This concentration of expertise allows for precise molecular staging, which is critical for determining the specific medulloblastoma subtype and tailoring therapy.
Patient Consensus: Patients emphasize that prognosis is highly risk-dependent and appreciate that many cases are potentially curable with aggressive, multidisciplinary care. They note that long-term monitoring is necessary to manage side effects like cognitive changes and endocrine health.
Total treatment for medulloblastoma in South Korea typically lasts between 6 to 12 months. This timeframe includes initial tumor removal followed by several weeks of recovery. Most patients then undergo multiple cycles of radiation and chemotherapy to eliminate remaining cancer cells.
Bookimed Expert Insight: Data from leading Seoul centers like Severance Hospital shows a focus on staged protocols. Initial surgery is just the first step of a year-long journey. Clinics here utilize digital systems like BESTcare to manage these complex, multi-month timelines. This reduces human error during the transition from neurosurgery to long-term oncology cycles.
Patient Consensus: Patients emphasize that treatment is a marathon of different stages rather than one hospital stay. They note that the start of radiation depends entirely on how quickly the surgical site heals.
South Korean hospitals offer proton beam therapy for paediatric patients with medulloblastoma. Leading centres like Samsung Medical Center and the National Cancer Center provide pencil beam scanning. This technology treats brain tumours while sparing developing tissue. Specialists like Dr Do Hyun Nam manage these complex cases.
Bookimed Expert Insight: While many centres treat adult cancers, only a few specialise in paediatric proton therapy. Samsung Medical Center and Severance Hospital stand out by partnering with leading US paediatric institutions. This means protocols for medulloblastoma align with the highest global standards for developing brains.
Patient Consensus: Patients note proton therapy is vital for medulloblastoma. It reduces radiation to healthy tissue. Many recommend sending pathology reports to South Korea early. This confirms the diagnosis and appointment dates.
Standard care in Korea involves maximal safe surgical resection. This is followed by risk-adapted radiotherapy and intensive chemotherapy. Major Seoul centres use molecular subgrouping to tailor protocols. This approach achieves high survival rates. It relies on precise craniospinal irradiation. For high-risk cases, it also includes tandem high-dose chemotherapy with stem cell rescue.
Bookimed Expert Insight: Korea's leading hospitals are massive clinical hubs. Neurosurgeons and oncologists work in the same building. Severance Hospital alone treats 4 million patients annually. This enormous volume means Korean specialists see rare medulloblastoma subtypes weekly. These doctors often partner with top US institutions like MD Anderson. This brings global expertise to every case.
Patient Consensus: Patients note that Korean hospitals require local pathology confirmation from original slides before starting. This process is thorough. Teams remain open to providing second opinions on existing international diagnoses. Residents emphasise that large tertiary university hospitals are the standard choice. This applies to complex cancer treatment in Korea.
South Korean medical centres report a 5-year overall survival rate between 75% and 85% for standard-risk medulloblastoma cases. Specialised paediatric protocols in Seoul have achieved 5-year survival rates as high as 95.8%. Outcomes depend heavily on surgical resection success and molecular tumour subtypes.
Bookimed Expert Insight: South Korea's survival rates are bolstered by high-volume Gamma Knife centres. Seoul National University Hospital maintains a 90% success rate with this technology. This experience is vital for medulloblastoma. Specialists like Dr Do Hyun Nam manage both paediatric and adult cases. This supports continuity of care as patients transition into adulthood.
Patient Consensus: Patients emphasise finding the specific molecular subgroup, such as WNT or Group 3. This helps them understand the outlook. Korean teams often focus on aggressive therapy. This typically includes surgery followed by radiation and chemotherapy to achieve a cure.
Korean specialists treat medulloblastoma in children under 3 years using radiation-sparing protocols. This helps protect developing brains. Treatment prioritises maximal safe surgical resection followed by intensive chemotherapy. Major Seoul centres often employ tandem high-dose chemotherapy with autologous stem cell rescue. This delays or avoids craniospinal irradiation.
Bookimed Expert Insight: Many Korean neurosurgery departments handle massive volumes. This includes those at Seoul National University Hospital and Gangnam Severance Hospital. These centres perform between 1,300 and 3,800 neurosurgical interventions annually. This high frequency allows surgeons to refine techniques for delicate paediatric cases. It often results in higher success rates for complex tumour removals than lower-volume regional hospitals.
Patient Consensus: Families note that age and molecular subgroup are vital. These factors determine the choice between radiation-sparing plans and proton therapy. Parents often suggest asking specifically for proton therapy. This reduces damage to healthy brain tissue in toddlers.
South Korea has three leading neuro-oncology centres. They are Seoul National University Hospital (SNUH), Asan Medical Center, and Severance Hospital. These research-driven institutions use GammaKnife and robotic systems. They consistently appear in Newsweek’s World’s Best Hospitals list for specialised neurological and oncology care.
Bookimed Expert Insight: Major centres like Seoul National University Hospital (SNUH) are famous. However, their high volume means 30,000 international patients visit annually. For urgent medulloblastoma cases, Korea University Anam Hospital offers a distinct advantage. They provide same-day consultations, tests, and admission for new cancer patients to expedite treatment.
Patient Consensus: Patients say that Samsung Medical Center and Asan Medical Center are top-tier cancer centres. They suggest prioritising the clinic that offers the fastest expert review for urgent cases.
South Korea actively conducts clinical trials and intensive salvage protocols for relapsed medulloblastoma. Treatment focuses on high-dose chemotherapy and autologous stem cell transplantation. Major centres lead research through the Korean Society for Pediatric Neuro-Oncology (KSPNO). These include Severance Hospital and Seoul National University Hospital.
Bookimed Expert Insight: Many Australian families look for trials in the US. However, South Korean centres like Severance Hospital maintain direct research partnerships with the Children's Hospital of Philadelphia. This link allows Korean specialists to implement advanced paediatric protocols quickly. Data shows these high-volume centres treat thousands of international patients annually. They offer a sophisticated alternative for complex relapses.
Patient Consensus: Families note that relapsed cases often require trial hunting beyond standard surgery and radiation. Research shows searching for specific paediatric neuro-oncology protocols works better in the Republic of Korea. This approach is more effective than looking for general brain cancer programmes.